-
Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia/LymphomaDaiichi Sankyo2021-12-13 15:00:35Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia/Lymphoma
-
ENHERTU® Additional Analyses Further Reinforce Groundbreaking Efficacy in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-12-09 09:38:01ENHERTU® Additional Analyses Further Reinforce Groundbreaking Efficacy in Patients with HER2 Positive
-
Datopotamab Deruxtecan Continues to Show Promising Durable Response and Disease Control in Patients with Metastatic Triple Negative Breast CancerDaiichi Sankyo2021-12-07 11:55:07Datopotamab Deruxtecan Continues to Show Promising Durable Response and Disease Control in Patients with
-
Daiichi Sankyo to Present New Breast Cancer Data Across DXd ADC Portfolio at 2021 SABCSDaiichi Sankyo2021-11-30 20:50:31Daiichi Sankyo to Present New Breast Cancer Data Across DXd ADC Portfolio at 2021 SABCS
-
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast CancerDaiichi Sankyo2021-11-30 12:57:07DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive
-
Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed FLT3-ITD Positive AMLDaiichi Sankyo2021-11-21 16:27:52Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in
-
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast CancerDaiichi Sankyo2021-11-18 11:23:39TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive,
-
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive Advanced Gastric CancerDaiichi Sankyo2021-11-02 18:39:15Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive
-
Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2021-10-24 15:53:34Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA®
-
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based RegimensDaiichi Sankyo2021-10-04 08:46:17ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Positive Metastatic Breast
